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Abstract: Drug encapsulation in nanocarriers such as polymeric nanoparticles (Nps) may help to overcome the limitations
associated with cannabinoids. In this study, the authors’ work aimed to highlight the use of electrospraying techniques for the
development of carrier Nps of anandamide (AEA), an endocannabinoid with attractive pharmacological effects but
underestimated due to its unfavourable physicochemical and pharmacokinetic properties added to its undesirable effects at the
level of the central nervous system. The authors characterised physicochemically and evaluated in vitro biological activity of
anandamide/ɛ-polycaprolactone nanoparticles (Nps-AEA/PCL) obtained by electrospraying in epithelial cells of the human
proximal tubule (HK2), to prove the utility of this method and to validate the biological effect of Nps-AEA/PCL. They obtained
particles from 100 to 900 nm of diameter with a predominance of 200–400 nm. Their zeta potential was −20 ± 1.86 mV. They
demonstrated the stable encapsulation of AEA in Nps-AEA/PCL, as well as its dose-dependent capacity to induce the
expression of iNOS and NO levels and to decrease the Na+/K+ ATPase activity in HK2 cells. Obtaining Nps-AEA/PCL by
electrospraying would represent a promising methodology for a novel AEA pharmaceutical formulation development with
optimal physicochemical properties, physical stability and biological activity on HK2 cells.
1 Introduction
Cannabinoids and their derivatives – both natural and synthetic
origin –, represent an interesting therapeutic potential in
cardiovascular diseases such as arterial hypertension, also as
antiemetic and stimulants of appetite in debilitating diseases,
analgesics for the treatment of multiple sclerosis and cancer,
among other pathologies. However, despite its high clinical
potential, only some dosage forms are currently available due to
their unfavourable physicochemical and pharmacokinetic
properties added to the undesirable effects at the level of the central
nervous system associated with these therapies [1–4].
In this paper, medicine uses nanotechnology to direct
specifically the active ingredients towards their therapeutic target,
avoiding or reducing their side effects, increasing their solubility,
prolonging their release, as well as preventing their chemical,
photochemical, or oxidative degradation [5–7]. In this regard,
several authors have conducted research aimed at developing and
optimising various nanosystems for the administration of
cannabinoids for pharmaceutical use through the production of
micro and nanoparticles of lipid and polymeric nature [8, 9]. These
nanosystems have been shown to encapsulate the mentioned active
principles effectively, achieving an increase in their solubility and
stability, improving their absorption, protecting them from
premature enzymatic degradation or metabolism in the body,
prolonging their circulation time and limiting their side effects [5,
10].
Of particular interest, an article that examined the potential of
nanoparticles administered by inhalation to treat lung cancer
demonstrated that its use would provide a promising strategy for
overcoming the current clinical limitations of the unwanted
psychoactive effects of cannabinoids used in the treatment of this
type of tumours [1]. Similarly, some studies have demonstrated an
intense anticancer activity of the PEGylated and non-PEGylated
polymeric micro and nanoparticles, loaded with the
phytocannabinoid Δ(9)-tetrahydrocannabinol in lung cancer and
others [2, 3, 11–13]. Other scientific works reported that the
synthetic cannabinoid CB13 (which as a consequence of its poor
solubility in gastrointestinal fluids is not entirely absorbed orally)
encapsulated in nanoparticles of polylactic-co-glycolic acid coated
with polyethylene glycol [14, 15], showed a remarkable analgesic
efficacy with a very prolonged pain relief effect that lasted up to
eleven days after the administration of an oral dose compared to
free CB13 [16]. It was also shown the development of WIN
nanomicelles (synthetic cannabinoid with potent anticancer effects)
conjugated with maleic styrene acid reduces side effects and
increases the efficacy of the drug [17]. Similar results were found
when analysing the antitumour activity of cannabidiol released
from microparticles of epsilon polycaprolactone (PCL) showing
potential therapeutic advantages over the free drug [3].
In the particular case of the endocannabinoid anandamide
(AEA), it has been reported that its incorporation into spherical
PCL nanoparticles provided chemical stability for AEA in contact
with plastic materials and when stored as a liquid suspension in the
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dark. The strong affinity of the drug for the polymer showed a
prolonged passive diffusion rate of AEA through an artificial
model of lipid membrane [18]. Similarly, this same type of
nanoparticle was used to evaluate the existence of a membrane
transporter that regulates the extracellular levels of AEA,
demonstrating that the cellular uptake of AEA encapsulated in PCL
became much less sensitive to the inhibitors of the specific
transporter [19]. In both studies, the Nps-AEA/PCL was obtained
by nanoprecipitation. The use of the nanoprecipitation method is
not recommended for the loading of highly hydrolysable and
thermolabile drugs because it is a technique that consists of several
steps that include obtaining of particles in an aqueous medium and
subsequent drying stage, which makes it a particular, tedious and
lengthy procedure [20].
In relation to the aforementioned endocannabinoid and its renal
effects, a study carried out by Silva et al. reported that AEA was
able to increase the concentration of nitric oxide (NO) in cells of
the thick ascending limb of the loop of Henle through the
activation of cannabinoid receptor type 1 (CB1) receptors and the
subsequent signalling of the NO synthase (NOS) enzyme. The NO
produced would cause blockage of apical channels that carry
sodium in these cells, favouring its excretion as well as diuresis
[21]. Likewise, it has been demonstrated that renal epithelial cells
of the human proximal tubule (HK2) express the CB1 receptor
[22]. Additionally, it was also shown that the Na+/K+ ATPase pump
presents in the basolateral membrane of the renal proximal tubular
epithelium is one of the essential transporters responsible for
maintaining the volume and composition of extracellular fluid
through different signalling pathways [23].
Therefore, based on the background above, our laboratory
proposed as central objectives of the present work: first, to
synthesise polymeric nanoparticles carrying AEA (Nps-AEA/PCL)
by electrospraying technique. Second, to characterise them
regarding their main physicochemical properties; and, finally, to
evaluate their biological activity in HK2 cell cultures through the
measure of their ability to enhance the inducible isoform of NOS
(iNOS) expression and the determination of NO levels and their
impact over the Na+/K+ ATPase activity.
2 Materials and methods
2.1 Materials
ɛ-PCL was donated by the Instituto de Investigaciones en Ciencia y
Tecnología de Materiales (INTEMA-CONICET-UNMdP). AEA
brand Cayman Chemical (Michigan, USA) and quality pro-analysis
acetone from Laboratorios Cicarelli (Santa Fe, Argentina), were
utilised. Moreover, we used an infusion pump for syringes brand
KD Scientific, a high-voltage electric source (0–30 kV) brand
Gamma High Voltage Research, a glass syringe (to avoid corrosion
by the solvent) of 20 ml with diameter internal of 20 mm, a metal
needle and a metal collector plate covered with aluminium foil.
2.2 Preparation of PCL-nanoparticles charged with AEA
A 0.5% w/w solution of PCL in acetone was prepared. After the
complete dissolution of PCL, 5 mg of AEA was added. A glass
syringe was charged with the polymer solution prepared as
described above and mounted on the infusion pump. The pump was
programmed to a flow of 0.5 ml h−1, and an inner diameter of 20 
mm syringe. The needle-collector distance was 15 cm. The voltage
used was 10 kV. The particles were removed from the collector
with the help of a silicone spatula.
2.3 Spectroscopic characterisation by infrared spectroscopy
by Fourier transform (FTIR)
The FTIR spectra were recorded with a Nicolet Protégé 460
spectrometer, in the range of 4000–225 cm−1, with 64 scans and
spectral resolution of 4 cm−1. For the preparation of the pellets
(PCL and Nps-AEA/PCL), KBr was used as a spectroscopic
quality diluent, melted and then stored in an oven. The spectrum of
the AEA was collected from the commercial ethanolic solution of
the endocannabinoid using ZnSe windows.
2.4 Spectroscopic characterisation by UV–visible (UV–vis)
spectroscopy
The UV–vis absorption spectra of AEA and Nps-AEA/PCL in
ethanol were measured in quartz cells (optical path = 10 mm) in a
Shimadzu UV-160 spectrophotometer, equipped with a CPS-240A
cell positioner; the temperature was controlled at 25 ± 0.1°C.
2.5 Thermogravimetric analysis (TGA)
The TG curves were recorded on a Shimadzu TGA-51 instrument
from room temperature to 300°C, with 50 ml min−1 of nitrogen
flow and a heating rate of 5°C min−1. The samples were
appropriately placed in platinum cells.
2.6 Differential scanning calorimetry (DSC)
The DSC curves were recorded on Shimadzu DSC-60 equipment
from room temperature to 300°C under nitrogen atmosphere
flowing at 50 ml min−1, with a heating rate of 5°C min−1. PCL and
Nps-AEA/PCL were placed in open aluminium cells, while for
AEA, aluminium cells with perforated lid were used; in both cases,
an empty aluminium cell was used as a reference. The melting
temperature was determined as the peak of the process.
2.7 Scanning electron microscopy (SEM)
The SEM images were recorded to determine the morphology and
size of the Nps-AEA/PCL using a LEO1450DP microscope. The
sample was directly observed on the aluminium foil in which it was
collected, to which a gold cover was applied. The analysis of the
images obtained was carried out using ImageJ version 1.x image
processing software.
2.8 Dynamic light scattering (DLS)
DLS assessed the zeta potential as a measure of the surface charge
of the particles. It was determined at room temperature in a
Zetasizer® 3000HS (Malvern Instruments, UK). 1 mg dried Nps
was suspended in 1 ml of distilled water before measurement. The
analysis was carried out in triplicates.
2.9 Physical stability tests
In order to evaluate the physical stability of the Nps-AEA/PCL at
different temperatures, they were subjected to three different
temperature values (4, 25 and 40°C) during a period of four
months. The samples were analysed by FTIR at 30, 60 and 120
days in order to determine their physical stability.
2.10 Cell line and culture conditions
Human renal tubular epithelial HK2 (ATCC® Number:
CRL-2190™) were maintained in Dulbecco`s Modified Eagle
Media (DMEM, GIBCO®, Grand Island, NY, USA) and
supplemented with 10% foetal bovine serum (Internegocios®,
Mercedes, Buenos Aires, Argentina), 100 µg/ml streptomycin and
100 U/ml penicillin (GIBCO®, Grand Island, NY, USA) at 37°C in
a humidified atmosphere with 5% CO2.
2.11 Cells treatment
To perform the cellular protocol, 1 × 106 HK2 cells were seeded in
Petrís dishes (100 mm diameter, Biofil®, Argentina). After 24 h,
the supernatant was aspirated and the media was replaced with the
appropriate treatments: free AEA, was used at 1 and 10 µM; Nps-
AEA/PCL with encapsulated AEA was added to reach 1 and 10 
µM of AEA; PCL alone was added at 141 µg/ml (maximum
concentration reached when AEA was 10 µM) and; finally, the
control group did not receive any treatment. In the three treated
groups, AEA and nanoparticles were dissolved in control media.
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The treatments were performed for 24 h; then, cells were scrapped,
pelleted, washed with saline phosphate buffer (PBS) and stored at
−80°C until use. All tests were performed in duplicate.
2.12 iNOS protein expression by western blot technique
The HK2 cellular lysed were homogenised, and protein levels were
quantified by Bradford assay with bovine serum albumin (BSA)
10 mg/ml as a standard. Samples were prepared in sodium dodecyl
sulphate (SDS) sample buffer (31.25 mM Tris-HCl, pH 6.8, 10%
glycerol, 0.0025% bromophenol blue, 10 mM dithiothreitol, 1%
SDS). The samples containing 20 μg of proteins were
electrophoresed in SDS (0.1%) and 8% polyacrylamide gel with
4% stacking gel and then transferred to nitrocellulose. In the next
step, softly removed blot from the gel and placed it in a container
with 15 ml of Ponceau S protein staining solution. Immediately, we
proceeded to block the non-specific binding sites with 5% non-fat
dry milk in PBS plus 0.1% Tween for 1 h RT, washed and then
incubated overnight in the primary antibody against iNOS (C-11
mouse monoclonal, 1:2500) from Santa Cruz Biotechnology. We
used the β-actin expression as a housekeeping gene (C4, mouse
monoclonal antibody, 1:1500). Detection was accomplished with
secondary antibodies (DAKO). Densitometric analysis was carried
out by image analysis software, and the photographs were
digitalised by using a scanner (LACIE Silver Scanner for
Macintosh) and the Desk Scan software (Adobe Photoshop) on a
desktop computer. The immunosignal ratio was standardised to 1
for the appropriate control values (HK2 cells without treatment).
2.13 Determination of nitrite levels in HK2 cells
We measured nitrite levels by Griess reaction with minor
modifications [24]. Homogenates from lizated HK2 cells were
incubated with 10 mmo1/l l-Arginine in a buffer (pH 7.40)
containing 25 mmol/l HEPES, 140 mmol/l NaCl, 5.4 mmol/l KCl,
1.8 mmol/l CaCl2, 1 mmol/l MgCl2, and 5 mmol/l glucose at 37°C
for 24 h. After centrifugation at 6400 rpm for 20 min, the
supernatants were used for the assay of indirect NO production and
the amount was corrected by means of the protein amount,
measured according to the Bradford method. Nitrites were
measured by a spectrophotometer at 540 nm wavelength. The data
present were expressed as nmol of nitrite generated per μg protein
per 100 μl homogenate.
2.14 Assay for Na+/K+ ATPase activity
The ATPase activity was performed according to previous reports
[25]. HK2 cells were washed and suspended in a cold solution and
transferred to Eppendorf tubes. For the assay, each sample was
incubated at 37°C for 15 min with the presence of 1 mmol/l
adenosine 5′-triphosphate (ATP). After the incubation time, the
Eppendorf tube was immersed in a boiling water bath for 5 min.
The samples were centrifuged, and the free inorganic phosphate
produced was determinate in the supernatant fraction using the
malachite-green technique. The samples were diluted with
dissection solution up to 250 μl and mixed with 1 ml of the
malachite-green reagent 0.03% Na2MO4·2H2O, 0.02% malachite
green oxalate, 0.05% Triton X-100, and 0.7 mol/l HCl. Also was
added a volume of 0.1 mL sodium citrate solution (33%) to every
sample. Then samples were incubated for 30 min at RT. Optical
density was performed at 600 nm. The standard curve was obtained
incubating 200 μl of a known phosphate concentration solution
with 1 ml of malachite-green reagent.
Finally, Na+/K+ ATPase activity expressed as the picomole of
inorganic phosphate per minute incubation was determined by
quantifying the difference in inorganic phosphate released from
ATP in the absence and presence of ouabain (2 mM).
2.15 MTT assay
The potential cytotoxic activity of Nps-AEA/PCL was studied by
MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium
bromide)] assay with the aim of determining the cell viability.
Briefly, upon completion of the pharmacological treatment, HK2
cells were loaded with MTT to a final concentration of 0.5 mg/ml
and incubated for 4 h at 37°C. The chromogen formed was
dissolved in dimethyl sulfoxide (DMSO), and the optic density
value measured at 570 nm was used to index cell viability. The
absorbance of the untreated HK2 cells (controls) was also
estimated to calculate relative cell viability (in percentage). The
assay was performed in triplicate.
For the photographic record, 150,000 cells were plated on
coverslips located at the bottom of the six-well plate. After 24 h,
the same treatments as explained above were applied. After 24 h,
the medium was removed, two rinses were made with PBS, and the
cells were fixed with methanol for 30 min. Subsequently, they were
stained with crystal violet and mounted on slides.
2.16 Statistical analysis
In studies that required statistical analysis, the results were
assessed by two-way analysis of variance for comparisons among
groups. Differences among groups were determined by Bonferroni
post-test. A P < 0.05 was considered to be significant. Results are
given as means ± standard error medium (SEM). Statistical tests
were performed by using GraphPad In Sat version 3.00 for
Windows 95 (Graph Pad Software, Inc., San Diego, CA, USA).
3 Results
3.1 DSC analysis and TGA
Fig. 1 shows the DSC curves corresponding to the Nps-AEA/PCL
compared to those obtained for AEA and PCL separately. 
Specifically, in Fig. 1a, corresponding to AEA, an endothermic
signal is observed at 40.13°C (ΔHf = 2.65 kJ g−1), which can be
associated with the melting process of the endocannabinoid. The
fusion process of the polymer (Fig. 1b) is observed at 59.60°C
(ΔHf = 59.59 J g−1). The DSC curve corresponding to the Nps-
AEA/PCL (Fig. 1c) shows a single endothermic signal at 55.85°C
(ΔHf = 44.38 J g−1), evidencing an increase in the thermal stability
of AEA in the Nps-AEA/PCL in relation to free AEA.
In addition to DSC analysis, samples of PCL and Nps-
AEA/PCL were also evaluated thermogravimetrically (Fig. 2) in
order to corroborate the thermal behaviour in the temperature
ranges associated with the melting events observed in the DSC
curves. It was not observed a significant mass loss in the
temperature range corresponding to the melting processes, assigned
from the DSC analysis, so it is verified that the endothermic signals
of these substances can be assigned to their melting processes.
TGA was not performed for the ethanoic solution of AEA.
3.2 FTIR analysis
Due to the complexity of the obtained spectra, only the vibrational
modes of the main AEA and PCL functional groups potentially
associated with some interaction (Figs. 3A (a and b), respectively)
Fig. 1  DSC curves of
(a) AEA, (b) PCL, (c) Nps-AEA/PCL
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were analysed (Fig. 3B). This study allows detecting band shifts or
modifications that may be related to possible interactions between
the components of the system under study.
The FTIR spectrum of AEA shows broadband at 3351 cm−1,
which can be assigned to υ-(O–H); with a contribution of υ-(N–H).
Additionally, the weak band observed at 1654 cm−1 is assigned to
υ-(C– = –O) involved in intra- or inter-molecular H-bond
interactions justifying its position and intensity. In the spectrum of
PCL, the characteristic band of υ-(O–H) is observed at 3441 cm−1,
while υ-(C– = –O) is observed at 1737 cm−1. The FTIR analysis of
the Nps-AEA/PCL spectrum suggests potential inter-molecular
interactions between AEA and PCL. The υ-(C– = –O) vibrational
mode of PCL is shifting to lower wavenumber, indicating a
weakening of this bond. On the other hand, the υ-(O–H) and υ-(N–
H) vibrational modes of AEA are found to higher wavenumber,
due to the reinforcement of these bonds. These shiftings are
probably indicative of inter-molecular H-bond interactions between
AEA and PCL in the nanoparticles. The υ-(C– = –O) vibrational
mode of AEA in the Nps-AEA/PCL spectrum could not be
identified due to overlapping with PCL bands.
3.3 UV–vis analysis
The UV–vis spectra corresponding to AEA and Nps-AEA/PCL are
shown in Fig. 4. AEA presents two absorption bands centred at 208
and 241 nm, which could be attributed to π–π* transitions. A
bathochromic displacement of the band at 208 nm, the
disappearance of the band at 241 nm, and a significant decrease in
absorbance was observed in the UV–vis spectrum of Nps-AEA/
PCL. These facts can potentially suggest that in the process of
encapsulation of the endocannabinoid there are interactions
between both components of the system.
3.4 SEM and DLS analysis
Fig. 5 shows the SEM microphotographs of the Nps-AEA/PCL,
evidencing its spherical or ovoid and smooth surface nature. These
are distributed in a range of sizes between 100 and 900 nm, the
most predominant being those between 200 and 400 nm (Fig. 6),
considering a population of 100 particles. Additionally, the
presence of agglomerates of nanoparticles that affect the
homogeneity of the sample was observed. In terms of the surface
charge of the particles, their zeta potential was −20 ± 1.86 mV.
Fig. 2  TG curves of
(a) AEA, (b) Nps-AEA/PCL
 
Fig. 3  FTIR analysis
(A) Molecular structure of (a) AEA and (b) PCL, (B) FTIR spectra of (a) AEA, (b)
PCL and (c) Nps-AEA/PCL
 
Fig. 4  UV–vis spectra of AEA (black) and Nps-AEA/PCL (red)
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3.5 Physical stability tests
The evaluation of the physical stability of the Nps-AEA/PCL was
performed by storage the samples in real-time under different
temperature and humidity conditions during several periods, as
mentioned previously. The stability was checked by FTIR analysis
(Fig. 7), confirming that the samples remained unchanged in all the
conditions evaluated. This physical stability could be attributed to
the intermolecular interactions between AEA and PCL described
previously (see Section 3.2). In this sense, intermolecular
interactions have been found in other multi-component systems
with PCL [26] and they are responsible for the increased thermal
stability.
3.6 iNOS expression, NO levels, and Na+/K+ ATPase activity
in HK2 cells
Figs. 8–10 show overexpression of iNOS as well an augmented
production of nitrites, and a reduction in the Na+/K+ ATPase
activity in those cells that received treatment for 24 h with AEA
either encapsulated in Nps-AEA/PCL or non-encapsulated in them
compared to control, in a dose-dependent manner. Control and PCL
group levels were similar between them. Fig. 8 shows the bands
immunostained to reveal levels of iNOS in the HK2 cells. In 1 μM
concentration of AEA it was observed an iNOS expression
increased with values of 1.60 ± 0.30% for Nps-AEA/PCL and 2.65 
Fig. 6  Particle size distribution of Nps-AEA/PCL considering a
population of 100 particles
 
Fig. 7  FTIR spectra of solids from physical stability assay of Nps-
AEA/PCL at
(a) 30 days, (b) 60 days, (c) 120 days. Red, green and black colours correspond to a
storage temperature of the particles at 4, 25 and 40°C, respectively
 
Fig. 8  iNOS protein expression in HK2 cells by AEA treatment
(a) Western blot, (b) Histogram
 
Fig. 9  NO bioavailability in HK2 cells linked to AEA treatment
 
Fig. 10  Effect of Nps-AEA/PCL on Na+/K+ ATPase activity in HK2 cells
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± 0.30% for free AEA versus 1.00 ± 0.03% or 1.05 ± 0.03%; P
<0.05 or P <0.01 of control or PCL group, respectively. The
concentration of nitrites (Fig. 9) was of 80 ± 15% for Nps-
AEA/PCL and 110 ± 30% for free AEA versus 50 ± 10% or 60 ± 
10%; P <0.05 or P <0.01 of control or PCL group, respectively.
The Na+/K+ ATPase activity (Fig. 10) was of 30 ± 6% for Nps-
AEA/PCL and 22 ± 7% for free AEA versus 45 ± 5% or 42 ± 4%; P
<0.05 or P <0.01 of control or PCL group, respectively. Likewise,
in 10 μM concentration of AEA it was found an iNOS level rise
(Fig. 8) with values of 2.50 ± 0.25% for Nps-AEA/PCL and 5 ± 1%
for free AEA versus 1.00 ± 0.03% or 1.05 ± 0.03%; P <0.01 or P
<0.001 of control or PCL group, respectively. The concentration of
nitrites (Fig. 9) was of 120 ± 25% for Nps-AEA/PCL and 250 ± 
50% for free AEA versus 50 ± 10% or 60 ± 10%; P <0.01 or P
<0.001 of control or PCL group, respectively. The Na+/K+ ATPase
activity (Fig. 10) was of 20 ± 8% for Nps-AEA/PCL and 5 ± 2%
for free AEA versus 45 ± 5% or 42 ± 4%; P <0.01 or P <0.001 of
control or PCL group, respectively. Of special interest, these
studies show a remarkable difference between AEA encapsulated
and non-encapsulated in PCL matrix related to its ability for
increasing iNOS expression and NO production and decreasing Na
+/K+ ATPase activity. This phenomenon could be because the AEA
release from Nps would depend on the erosion and dissolution of
the PCL matrix. Therefore, it would be carried out in a gradual and
controlled manner compared to the treatment with AEA in free
form.
3.7 Cytotoxicity study for Nps-AEA/PCL
As shown in Fig. 11a, in none of those treatments, applied changes
in viability were observed; and in the same way, as seen in
Fig. 11b, after 24 h of treatment the difference in cell morphology
was minimal, and no significant changes were evidenced. 
4 Discussion
The results of the present study show in an unprecedented way the
satisfactory obtaining of Nps-AEA/PCL by means of the
electrospraying technique, whose physical–chemical properties
were related to its thermal stability, dimensions, biologicals activity
and drug–polymer interactions.
Regarding the results of the thermal analysis performed on the
Nps-AEA/PCL, it was observed that the melting temperature of
AEA was shifted to lower values with respect to the melting point
reported by Aberturas et al. [18]. On the other hand, the melting
point in the polymer agrees with bibliographic data [27, 28]. The
absence of any additional signal in the thermal curve of the Nps-
AEA/PCL would indicate this effectively encapsulated in them
[29]. The DSC analysis showed an increase in the thermal stability
of AEA in the Nps-AEA/PCL with respect to free AEA, in
agreement with that reported for other PCL-based nanocomposites
[30], which would be a highly desired effect in the development of
this type of formulations.
Furthermore, FTIR spectroscopy has been used as a powerful
tool for the characterisation of nanoparticles [31, 32]. Specifically,
as outstanding data, our study proved the existence of drug–
polymer interactions that were also observed in other
nanoparticulate systems based on PCL [33]. This is another
unpublished data of our work since it is known that other studies
have reported that PCL does not always establish this type of
interaction with the drug that it is incorporated in similar
nanostructures [34, 35]. The changes observed between the UV-Vis
spectra of free AEA and the Nps-AEA/PCL would also indicate the
interaction between both components, since other authors have
shown that no bathochromic displacements were observed in the
UV–vis spectra of drugs and polymers that do not interact with
each other at the nanoscale [36]. This fact would suggest the
successful encapsulation of AEA in the Nps-AEA/PCL [37],
consistent with our current results obtained from DSC analysis.
Unprecedentedly – and from the exhaustive search in the most
current literature – the finding emerges that our study is the first to
show the development of AEA/PCL nanoparticles by the
electrospraying technique. Other authors have achieved to
synthesise this same type of nanoparticles but using the
nanoprecipitation method [18, 19]. In general – compared to other
processes for obtaining nanoparticles – electrospraying offers
essential advantages like better control of the characteristics of
these nanostructures due to a large number of variables that can be
modified by this technique. Electrospraying can achieve a uniform
dispersion of the drug within the polymer matrix with minimal loss
of the drug [38]. The ease of operation (one-step process) and
profitability are other attractive features of these processes.
Furthermore, the direct obtaining of the product in the solid-state
eliminates an additional drying step, decreasing the appearance of
problems related to the stability of the particles [39]. Despite the
large particle size and polydispersity are usually considered a
disadvantage of electrospraying, we think that this aspect could be
used to obtain a longer duration of the drug release. It is because
small particles which exhibit a large surface area would undergo
disintegration of their matrix and release of the drug in a first stage,
while larger size particles would go through the same process in a
longer period of time, extending the therapeutic function of the
nanoparticulated formulation. Future studies of in vitro release
should be performed to prove this fact, but we considered that this
goes beyond the objectives of this work.
The structural analysis by electronic microscopy allowed us to
characterise size and shape, but also allowed to identify the
presence of particle agglomerates in the SEM image. These
formations could be related to temporary blockages of the needle
through which the polymer solution circulates and/or the inherent
unctuous consistency of the endocannabinoid. Additionally, we
consider as another frequent cause of the formation of
agglomerates, the absence of stabilising agents such as surfactants
or emulsifiers in the formulation of the polymer solution used to
obtain the Nps-AEA/PCL [40]. However, and as verified in the
physical, chemical and biological tests, these agglomerates did not
affect the results.
As for the physicochemical stability of AEA, it is known that
because it is a derivative of arachidonic acid it is highly susceptible
to oxidative thermal degradation. Of interest, FTIR has been used
by other authors to evaluate this possible degradation on
arachidonic acid [41]. That is why AEA has a storage temperature
of −20°C. In this sense, it results particularly remarkable that the
stability tests carried out on the Nps-AEA/PCL showed that AEA
is stable even at temperatures of 40°C during a period of 4 months.
This result suggests that our formulation of Nps-AEA/PCL would
represent a useful option to stabilise an active ingredient labile as
AEA, facilitating, in turn, the preservation conditions of this novel
pharmaceutical formulation.
In addition to the physicochemical characterisation of the Nps-
AEA/PCL obtained, we carried out in vitro biological activity tests
as the quantification of iNOS expression in human proximal
tubular epithelial cells. It is known that this inducible isoform of
Fig. 11  MTT assay
(a) Cell viability, (b) Cell morphology
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NOS is widely expressed in cells of the renal proximal tubule [42].
To highlight, several studies have reported on a promising
antihypertensive effect (primarily vasodilator) of AEA mediated by
NO release in different cell types [43–45]. Nevertheless, the
aforementioned effect, specifically related to renal ion transport,
currently has not been demonstrated through the administration of
AEA encapsulated in polymeric nanoparticles. In fact,
unpublished, our results would demonstrate for the first time that
the Nps-AEA/PCL were able to increase in a dose-dependent
manner the expression of iNOS in HK2 cells, with the consequent
increase in NO production by these cells. In order to complement
the findings, we also decided to evaluate the effect of Nps-
AEA/PCL on Na+/K+ ATPase activity. In this sense, we
demonstrated a dose-dependent decrease in Na+/K+ ATPase
activity, confirming our initial hypothesis. Finally, although it is
known that in some circumstances the NO derived from iNOS is an
important mediator of the apoptosis of tubular epithelial cells
induced by macrophages in vitro [46], we demonstrated that at the
concentrations produced in our work no cytotoxicity was observed.
This aspect constitutes one more point in favour of the use of AEA,
especially encapsulated in Nps, in order to modulate the activity of
the Na+/K+ ATPase in HK2 cells.
5 Conclusions
The use of biocompatible, biodegradable and non-toxic organic
polymers such as PCL would allow the development of new
pharmaceutical formulations for the controlled/prolonged release
of various types of active ingredients with attractive
pharmacological properties such as AEA but dismissed for their
physicochemical and pharmacokinetic limitations and
disadvantages. Our study demonstrated synthesis efficiency and
stability of this compound, also proved the ability of Nps-
AEA/PCL to decrease Na+/K+ ATPase activity at the renal level in
a mechanism that could be related to the iNOS expression and NO
levels (Fig. 12 or graphical abstract). Future in vivo studies should
be performed to demonstrate the usefulness of Nps-AEA/PCL in
cardiovascular pathologies treatment such as arterial hypertension
and other related diseases.
Finally, the strategies of active targeting (decoration of Nps
surface with ligands for specific receptors), passive targeting
(regulation of the Nps size and surface properties) or physical
targeting (using physical forces such as the application of a
magnetic field to guide Nps) are of special interest when designing
new nanoparticulate systems for drug delivery. In this sense,
different pharmacological targeting strategies could be used in the
future to achieve the specific localisation of these Nps-AEA/PCL
in sites of interest such as the kidneys or other cardiovascular
organs.
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